Testosterone Oral

Introduction Overview

Generic Name

testosterone oral

Brand Name

Jatenzo

Dosage Form

liquid-filled oral capsule

Drug Class

Androgens and anabolic steroids

Pharmacokinetics

Absorption:
Jatenzo is administered as a liquid-filled oral capsule designed to optimize the absorption of testosterone undecanoate. Unlike other oral testosterone formulations, Jatenzo uses a special self-emulsifying drug delivery system which facilitates enhanced gastrointestinal absorption, particularly through the lymphatic system, bypassing extensive hepatic first-pass metabolism. Absorption is significantly improved when taken with food, especially meals containing fats, as fat stimulates bile secretion aiding in emulsification and lymphatic uptake of the lipophilic ester. Clinical pharmacokinetic studies demonstrate that Jatenzo achieves therapeutically effective serum testosterone concentrations when administered twice daily with food. Absorption variability is influenced by individual patient factors such as gastrointestinal motility, concomitant food intake, and enterohepatic circulation.

Distribution:
After absorption, testosterone undecanoate, the active moiety in Jatenzo, is widely distributed in tissues, binding primarily to sex hormone-binding globulin (SHBG) and albumin in plasma. Only the free fraction of testosterone is bioactive at androgen receptors. The drug demonstrates extensive tissue penetration, affecting androgenic target organs including the prostate, skin, muscles, and central nervous system. Distribution volume varies by patient weight and body composition, with lipophilic characteristics favoring storage in adipose tissue and muscle. The extent of protein binding affects both drug availability and half-life. Testosterone and its metabolites also cross the blood-brain barrier, influencing behavior and mood.

Metabolism:
Testosterone undecanoate undergoes rapid enzymatic hydrolysis by nonspecific esterases in plasma and liver tissue, releasing active testosterone. Testosterone itself is extensively metabolized primarily in the liver via reduction to dihydrotestosterone (DHT) by 5-alpha reductase, and aromatization to estradiol by aromatase enzymes. These metabolites exert additional androgenic and estrogenic effects, respectively. Phase I metabolism involves hydroxylation and oxidation pathways, while Phase II includes conjugation reactions producing sulfate and glucuronide metabolites for renal excretion. The pharmacological activity and side effect profile are influenced by the balance of testosterone and its metabolites. Hepatic metabolism is subject to interpatient variability due to genetics, liver function, and concomitant drugs that induce or inhibit metabolic enzymes.

Elimination:
Testosterone and its metabolites are eliminated through both renal and fecal routes. Following hepatic metabolism and conjugation, water-soluble metabolites are excreted primarily in urine as glucuronides and sulfates. A smaller proportion is eliminated via bile into feces. The half-life of Jatenzo is extended relative to other oral testosterone formulations due to lymphatic absorption and slow release from tissue stores, allowing twice-daily dosing. Renal function can impact elimination rates; however, no significant accumulation was observed in patients with mild to moderate renal impairment. The drug's clearance is influenced by liver function, as extensive metabolism there precedes elimination. Understanding elimination properties is crucial for dose adjustment in patients with hepatic or renal disease.

Dosage Forms

Available Dosage Forms:
Jatenzo is available as a liquid-filled oral capsule containing testosterone undecanoate. The capsules are formulated specifically for oral administration with improved bioavailability compared to traditional oral testosterone esters.

Dosages for Adults and Adolescents:
The recommended starting dose in adult men with hypogonadism is 237 mg administered orally twice daily (morning and evening) with food. Dosage adjustments are guided by serum testosterone levels, symptom relief, and tolerability. Frequent blood monitoring of testosterone levels and blood pressure is required to optimize therapy and mitigate risks.

Specific Patient Populations:
Jatenzo is indicated specifically for adult males diagnosed with hypogonadism due to disorders of the testicles, pituitary gland, or hypothalamus. It is not approved for pediatric use; safety and efficacy in children under 18 years are unknown because testosterone may adversely affect bone growth. It is contraindicated in women and should not be used in males with age-related low testosterone or endocrine tumors. Careful dose titration and monitoring are advised in patients with cardiovascular disease, liver or kidney impairment, or risk factors for prostate cancer.

Specific Dosage Form Values:
- Oral liquid-filled capsule: 237 mg testosterone undecanoate per capsule
- Dosage regimen: 237 mg capsule taken twice daily with meals

Mechanism Of Action

Jatenzo exerts its therapeutic effects by acting as a synthetic replacement for endogenous testosterone, the principal androgen responsible for male sexual development and maintenance. Upon oral administration, testosterone undecanoate is absorbed and hydrolyzed to release active testosterone, which binds to androgen receptors in target tissues.

At the molecular level, testosterone diffuses into androgen-responsive cells and binds intracellular androgen receptors, forming a hormone-receptor complex. This complex translocates into the nucleus where it binds specific androgen response elements on DNA, altering gene transcription. This results in the synthesis of proteins essential for development and maintenance of male secondary sexual characteristics, anabolic effects on muscle and bone, and modulation of libido and mood.

Testosterone’s biochemical interactions include its conversion by 5-alpha reductase to dihydrotestosterone (DHT), a more potent androgen that exerts amplified androgen receptor activation, particularly in skin, prostate, and hair follicles. Additionally, aromatization to estradiol influences bone density and lipid metabolism, highlighting the complex endocrine interplay.

Clinically, Jatenzo restores physiologic serum testosterone levels in males with hypogonadism, alleviating symptoms such as fatigue, decreased libido, erectile dysfunction, anemia, and reduced muscle mass. Unlike transdermal or injectable formulations, Jatenzo’s oral administration offers improved patient compliance with effective systemic androgen delivery. Research supports its ability to maintain stable testosterone concentrations with twice-daily dosing.

Comparatively, Jatenzo’s mechanism is congruent with other testosterone replacement therapies but uniquely optimized for oral bioavailability via its lipid-based formulation facilitating lymphatic absorption, thereby minimizing first-pass hepatic degradation. This platform potentially reduces hepatic toxicity risks associated with traditional oral androgen therapies.

Extensive clinical studies demonstrate Jatenzo’s efficacy in normalizing testosterone levels and improving quality of life measures in hypogonadal men, with adverse effect profiles consistent with androgenic hormone replacement therapy.

Pharmacological Actions

Replaces endogenous testosterone in males with hypogonadism to restore normal androgen levels.
Binds to and activates androgen receptors to modulate gene transcription and protein synthesis.
Stimulates development and maintenance of male secondary sexual characteristics and reproductive function.
Exerts anabolic effects promoting muscle mass increase and bone density improvement.
Modulates libido, mood, and cognitive function via central nervous system androgen receptor activation.
Converted peripherally to dihydrotestosterone (DHT), enhancing androgen receptor activation in target tissues.
Aromatized to estradiol impacting bone metabolism and cardiovascular health.
Improves erythropoiesis by stimulating red blood cell production, correcting anemia.
Influences lipid metabolism and fat distribution through hormonal regulatory pathways.
Orally formulated to enhance lymphatic absorption, minimizing hepatic first-pass metabolism.
Demonstrates dose-dependent effects with pharmacokinetic stability on twice-daily administration.
May increase blood pressure as a systemic endocrine effect.
Potential to enlarge prostate tissue due to androgenic stimulation.
Habit-forming potential reflecting controlled substance scheduling due to abuse risk.
May alter mood and behavior, including risk for depression or aggressive tendencies.

Therapeutic Or Clinical Uses

Treatment of adult males diagnosed with hypogonadism due to disorders of the testicles, pituitary gland, or hypothalamus.
Replacement therapy to restore serum testosterone to physiologic levels in testosterone deficiency.
Alleviation of symptoms related to low testosterone including fatigue, diminished libido, erectile dysfunction, and mood disturbances.
Improvement of muscle mass, strength, and bone mineral density in testosterone-deficient men.
Correction of anemia associated with low testosterone levels.
Management option when injectable or transdermal testosterone formulations are contraindicated or not tolerated.
Use in men without age-related testosterone decline (not approved for age-related hypogonadism).
Supportive treatment for maintaining secondary sexual characteristics in men with hypogonadism.
Potential improvement in quality of life and sexual function indicators.
Therapeutic agent in patients with central or primary hypogonadism confirmed by laboratory testing.

Side Or Adverse Effects

Elevation of blood pressure with associated risks of cardiovascular events such as heart attack and stroke.
Increased red blood cell count (polycythemia), increasing the risk for thrombosis.
Prostate enlargement (benign prostatic hyperplasia), which may cause urinary difficulties.
Breast tissue swelling or tenderness (gynecomastia).
Changes in mood or behavior including depression, anxiety, and potential suicidal ideation.
Sleep apnea or exacerbation of pre-existing sleep-disordered breathing.
Nausea, heartburn, and gastrointestinal discomfort including burping and diarrhea.
Headache and migraine exacerbations.
Swelling of lower extremities (edema).
Joint, muscle, or back pain associated with androgenic effects on musculoskeletal tissues.
Cold or upper respiratory symptoms potentially related to hormonal modulation of immune responses.
Erections more frequent or prolonged than usual (priapism).
Weight gain secondary to anabolic hormonal action.
Hepatic dysfunction manifesting as loss of appetite, right upper quadrant pain, jaundice, and abnormal liver function tests.
Risk of allergic reactions including hives, facial swelling, and respiratory distress.

Precautions

Avoid use in patients with known or suspected prostate cancer or male breast cancer.
Use caution in patients with or at risk of cardiovascular disease, including hypertension, heart attack, or stroke.
Regular monitoring of blood pressure is mandatory during treatment.
Monitor hematocrit and hemoglobin to detect polycythemia.
Close supervision in patients with liver or kidney disease.
Careful dose titration and hormone level monitoring to avoid supra-physiological androgen exposure.
Use with caution in patients with sleep apnea or respiratory disorders such as COPD.
Monitor prostate-specific antigen (PSA) levels and urinary symptoms due to risk of prostate enlargement.
Not advised for use in elderly men with age-related testosterone decline or untreated hypothyroidism.
Avoid use in women and pediatric populations due to lack of safety data.
Potential to impair fertility; discuss reproductive plans prior to therapy initiation.
Risk of psychological effects necessitating assessment for mood disorders, depression, or suicidal ideation.
Store securely due to controlled substance status and abuse potential.
Avoid sharing medication to prevent misuse or accidental overdose.
Advise patients to take Jatenzo with food to optimize absorption.

Warnings

Contraindicated in patients with known or suspected prostate or male breast cancer.
Not indicated for treatment of low testosterone due to aging ('age-related hypogonadism').
May increase blood pressure, raising the risk of heart attack, stroke, or death.
Discontinue or modify therapy if significant elevation in blood pressure or cardiovascular symptoms develop.
Potential for serious adverse effects including liver injury, blood clots, or prostate hypertrophy.
May exacerbate or unmask sleep apnea causing respiratory complications.
Do not use Jatenzo to enhance athletic performance or physical appearance; abuse may lead to serious health consequences.
Risk of allergic reactions including anaphylaxis.
Habit-forming potential classified as a Schedule III controlled substance; misuse can result in addiction or fatal overdose.
Accidental ingestion of even a single dose can lead to fatal outcomes, particularly in children.
Monitor for signs of blood clots such as swelling, pain, shortness of breath, or chest pain.
Abrupt discontinuation without medical supervision may cause adverse hormonal imbalance.
Regular laboratory and clinical evaluations required to ensure safe and effective therapy.
Patients should be informed about potential behavioral changes and advised to report mood alterations.
Storage and disposal should follow regulatory guidelines to prevent diversion or accidental exposure.

Contraindication

Known hypersensitivity or allergy to testosterone or any component of Jatenzo capsules.
History or presence of prostate cancer.
History or presence of male breast cancer.
Low testosterone levels due solely to aging (age-related hypogonadism).
Women who are or may become pregnant, due to risk of fetal harm.
Children and adolescents less than 18 years old due to adverse effects on bone growth.
Severe hepatic impairment due to altered metabolism and risk of accumulation.
Uncontrolled cardiovascular disease where androgen therapy may exacerbate symptoms.
Patients with untreated severe sleep apnea or respiratory insufficiency.
Patients with active or recent thromboembolic events.
Patients with polycythemia or elevated hematocrit levels.
Patients currently abusing or with a history of anabolic steroid abuse.
Use with caution in patients with psychiatric disorders without appropriate monitoring.

Drug Interactions

Warfarin and other anticoagulants (Coumadin, Jantoven, apixaban, rivaroxaban, dabigatran) – increased risk of bleeding or altered anticoagulant effect.
Insulin – testosterone may alter glucose metabolism affecting insulin requirements.
Corticosteroids such as prednisone or dexamethasone – combined use may exacerbate fluid retention and edema.
Medications for pain, cough, or cold symptoms potentially interfering with metabolism or increasing side effect risks.
Drugs that induce or inhibit cytochrome P450 enzymes affecting testosterone metabolism (e.g., rifampin, ketoconazole).
Other hormonal therapies potentially causing additive androgenic effects or endocrine disruption.
Lipophilic drugs or those requiring lymphatic absorption might compete with Jatenzo, affecting bioavailability.
Agents that affect hepatic blood flow or liver function, altering testosterone clearance.
Concomitant use with antidiabetic agents requires monitoring for altered glycemic control.
Medications known to increase blood pressure may have synergistic hypertensive effects.
Drugs that increase hematocrit or erythropoiesis may exacerbate polycythemia risk.
Sedatives or central nervous system depressants could have enhanced effects due to mood alterations caused by testosterone.
Potential interactions with herbal supplements or vitamins that affect hormone levels or liver enzymes.
Any other prescription or OTC medications should be reviewed for interactions due to testosterone’s broad systemic effects.
Regular consultation with healthcare providers is essential to manage potential drug interactions safely.

Preparations Of The Drug

Liquid-filled oral capsules containing 237 mg testosterone undecanoate per capsule.
Formulated for enhanced oral bioavailability using a self-emulsifying drug delivery system to facilitate lymphatic absorption.
Packaged for oral administration with dosage scheduling twice daily with food.
Available only by prescription and classified as a Schedule III controlled substance due to testosterone content.
Storage instructions recommend keeping the medication at room temperature, away from moisture and heat.
Single dose packaging designed to discourage accidental ingestion and facilitate adherence.
Patient information leaflets and medication guides provided to outline usage, monitoring, and risks.
Manufacturer provides copay assistance programs to help offset cost due to the medication's expense.
Controlled substance regulations require safe storage and disposal practices, including drug take-back options.
Not available in topical or injectable forms under the Jatenzo brand name; other brands provide alternative delivery systems.
Compatible with standard oral administration, requiring no special preparation prior to use.
Each capsule is uniform in testosterone content ensuring consistent dosing.
Formulation designed to minimize first-pass liver metabolism compared to traditional oral androgens.
Packaging includes warnings about abuse potential, overdose risk, and accidental ingestion hazards.
Requires physician monitoring and dose adjustment based on serum testosterone measurements and clinical response.